![[The University of Leicester]](unilogo.gif)
MRC HSRC Workshop
"The Use of Evidence in Economic Decision Models"
The recent methods guidelines for health technology assessments from NICE (2004) recommend ‘all relevant evidence must be identified’ and ‘evidence must be identified, quality assessed and, where appropriate, pooled using explicit criteria and justifiable and reproducible methods’. The guidelines also state that ‘explicit criteria by which studies are included and excluded’ should be presented.
Two workshops, funded by an MRC HSRC workshop grant, were organised with the aim of producing specific procedural guidance to complement the NICE guidance and to provide a clear definition of all relevant evidence in the context of decision-analytical modelling.
WORKSHOP 1: Establishing the current situation
Dr Zoe Philips, University of Nottingham & Laura Ginnelly, University of York
“Review of guidelines for good practice in decision-analytic modelling in health technology assessment”
Dr Nicola Cooper, University of Leicester
“Use of evidence in decision models: An appraisal of health technology assessments in the UK since 1997”
Dr Carole Longson, National Institute for Clinical Excellence
“View from NICE – current issues”
Longson.ppsSuzy Paisley, University of Sheffield
“Identifying evidence for decision analytic models”
Paul Tappenden, University of Sheffield
“Ideal versus practical issues of using all available evidence to inform decision model
parameters”
Debbi Caldwell, University of Bristol
“The potential role of mixed treatment comparisons”
Dr Alex Sutton
“Discussion”
WORKSHOP 2: Methodology for appropriate use of evidence in decision models
Louise Longworth, NICE
“Guidelines reporting of evidence identification for the and selection in decision models: the NICE perspective”
Jim Chilcott, Suzy Paisley, University of Sheffield
“Systematizing the process: the role of problem structuring methods (PSM) in informing model structure”
Chilcott Paisley Tappenden.pps
Boby Mihaylova, Senior Researcher, University of Oxford.
“Advantages of individual patient data”
Dr Rebecca Turner, MRC Biostatistics Unit, Cambridge
“Addressing differences in rigour and relevance of evidence - a review of existing methods”
Dr Karl Claxton, Dr Neil Hawkins, University of York
“Optimising Drug Development and Efficient Licensing and Reimbursement Rules: The Role of Value of Information Analysis”.
Prof Tony Ades, University of Bristol
“What can we learn from data? A comparison of direct, indirect and observational evidence”
Dr Alex Sutton, University of Leicester
“Discussion”
